A retrospective study to evaluate outcomes and predictors of survival in patients with hepatocellular carcinoma and macrovascular invasion treated with sorafenib
Latest Information Update: 11 Mar 2016
Price :
$35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Mar 2016 New trial record